Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Operating Leases: 2019-2024

Historic Operating Leases for Amicus Therapeutics (FOLD) over the last 6 years, with Dec 2024 value amounting to $45.1 million.

  • Amicus Therapeutics' Operating Leases fell 9.54% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year decrease of 9.54%. This contributed to the annual value of $45.1 million for FY2024, which is 21.19% down from last year.
  • As of FY2024, Amicus Therapeutics' Operating Leases stood at $45.1 million, which was down 21.19% from $57.2 million recorded in FY2023.
  • Over the past 5 years, Amicus Therapeutics' Operating Leases peaked at $60.1 million during FY2022, and registered a low of $45.1 million during FY2024.
  • For the 3-year period, Amicus Therapeutics' Operating Leases averaged around $54.1 million, with its median value being $57.2 million (2023).
  • Per our database at Business Quant, Amicus Therapeutics' Operating Leases climbed by 18.43% in 2022 and then dropped by 21.19% in 2024.
  • Amicus Therapeutics' Operating Leases (Yearly) stood at $52.5 million in 2020, then declined by 3.25% to $50.8 million in 2021, then climbed by 18.43% to $60.1 million in 2022, then dropped by 4.87% to $57.2 million in 2023, then dropped by 21.19% to $45.1 million in 2024.